October 13, 2023 09:00 AM EDTUpdated October 13, 08:46 PM

Pfizer lands FDA approval for $6.7B ulcerative colitis drug, taking on antibodies as an oral alternative

Reynald Castañeda

Deputy Editor

Amber Tong

Pfizer has secured an FDA approval for etrasimod in moderate to severe ulcerative colitis. It’s the second sphingosine-1-phosphate (S1P) drug to arrive on the UC …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

Pfizer lands FDA approval for $6.7B ulcerative colitis drug, taking on antibodies as an oral alternative

Reynald Castañeda

Deputy Editor

Amber Tong

Sign up to read this article for free.

Trump team asked Warp Speed leader to head NIH, may seek more traditional pick for role

How did Trump’s FDA pick land? Biotech stocks are up, and executives are (mostly) relieved

Bristol Myers reveals more job cuts in New Jersey

Merck halts Phase 3 trial with PAH drug Winrevair following positive interim data

Trump taps Johns Hopkins researcher Marty Makary to lead the FDA; also names CDC, surgeon general picks

Incyte touts Monjuvi data from Phase 3 follicular lymphoma trial as it heads to FDA

Pfiz­er lands FDA ap­proval for $6.7B ul­cer­a­tive col­i­tis drug, tak­ing on an­ti­bod­ies as an oral al­ter­na­tive

Deputy Editor

Sign up to read this article for free.

more like this

Pfizer lands FDA approval for $6.7B ulcerative colitis drug, taking on antibodies as an oral alternative